Cergentis receives ISO/IEC 17025:2017 accreditation

Joris Schuurmans, CEO of Cergentis comments: Joris Schuurmans, CEO of Cergentis comments: "We are extremely proud that our Quality Management System has been accredited to comply with the ISO/IEC 17025:2017 standard. This recognition represents another milestone for Cergentis and underscores our team's commitment to quality. This acknowledgement not only demonstrates that we operate our genetic QC services within a robustly reliable compliant framework, but also reaffirms our mission to...

Joris Schuurmans, CEO of Cergentis comments:

"We are extremely proud that our Quality Management System has been accredited to comply with the ISO/IEC 17025:2017 standard. This recognition represents another milestone for Cergentis and underscores our team's commitment to quality. This acknowledgement not only demonstrates that we operate our genetic QC services within a robustly reliable compliant framework, but also reaffirms our mission to further advance genetic research."

About Cergentis

Cergentis is a genomics-focused biotechnology company, providing services and in-house solutions based on its proprietary genomic analysis platform to all leading biopharmaceutical companies and renowned research institutes. With our widely published and recognized genetic analyses, we support our global customer base in the characterization and QC of their genetically engineered models, biopharmaceutical cell line development and cell- and gene therapy products. By helping to de-risk R&D program decisions, minimizing time-to-clinic, providing objective genomic evidence for regulators, and supporting patient safety, we aim to support biopharmaceutical medicine development programs worldwide.

For more information, visit cergentis.com.

Logo: https://mma.prnewswire.com/media/1675871/Cergentis_Logo.jpg